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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
c o r r e s p o n d e n c e
Gigantism, Acromegaly, and GPR101 Mutations
To the Editor: Trivellin et al. (Dec. 18 issue)1 
report a recurrent activating GPR101 mutation 
(p.E308D) in 11 of 248 tumor DNA samples from 
patients with isolated acromegaly. Of these pa-
tients, 3 carried a germline GPR101 mutation. 
Two of the 3 patients are being treated at our 
institution and were identified among 38 pa-
tients from our cohort. This might suggest a 
higher prevalence of germline GPR101 mutation 
among French patients with sporadic acromegaly.
We therefore screened our entire cohort of 
263 patients with gigantism or acromegaly for 
germline mutations in GPR101, which encodes a 
G-protein–coupled receptor, and in AIP, which 
encodes aryl hydrocarbon receptor–interacting 
protein (Table S1 in the Supplementary Appen-
dix, available with the full text of this letter at 
NEJM.org). Only 3 patients (1.1%), including the 
2 patients who were reported previously, had the 
GPR101 p.E308D mutation; all 3 of these patients 
had adult-onset sporadic acromegaly. This find-
ing shows that the prevalence of this germline 
mutation in our large cohort is very similar to 
that reported by Trivellin et al. In addition, we 
identified in a patient with sporadic acromegaly 
a novel GPR101 p.D366E variant (0.4%), which 
was not reported in the databases of the Exome 
Aggregation Consortium (ExAC), 1000 Genomes 
Project, dbSNP, or Exome Variant Server. Germ-
line AIP mutations were identified in 8 of 263 
patients with somatotropinomas (3.0%), of 
whom 6 patients (75%) have gigantism.2 None of 
the 263 patients carried germline mutations in 
both GPR101 and AIP.
Peter Kamenický, M.D., Ph.D.
INSERM, Unité 693 
Le Kremlin-Bicêtre, France 
peter.kamenicky@u-psud.fr




Hôpitaux Universitaires Paris-Sud 
Le Kremlin-Bicêtre, France
No potential conflict of interest relevant to this letter was re-
ported.
1. Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acro-
megaly due to Xq26 microduplications and GPR101 mutation. 
N Engl J Med 2014;371:2363-74.
2. Lecoq AL, Kamenický P, Guiochon-Mantel A, Chanson P. 
Genetic mutations in sporadic pituitary adenomas — what to 
screen for? Nat Rev Endocrinol 2015;11:43-54.
DOI: 10.1056/NEJMc1500340
To the Editor: Trivellin et al. report a c.924G→C 
substitution (p.E308D) in GPR101 in 11 of 248 
patients with acromegaly, for an allele frequency 
for this variant (rs73637412) of 2.86%. At the 
time of manuscript preparation, a search of pub-
lic databases, including the 1000 Genomes Proj-
ect, the Exome Variant Sever, and the GO Exome 
Sequencing Project of the National Heart, Lung, 
and Blood Institute, did not identify the c.924G→C 
substitution in 7600 control individuals.
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Recently, a new exome-sequencing data set, 
the ExAC Browser, has become publicly avail-
able.1 It contains sequence data from approxi-
mately 61,500 unrelated individuals. A search of 
the ExAC Browser for the c.924G→C substitution 
shows an allele frequency of 0.55% (about 1 in 185) 
among Europeans and 0.36% (about 1 in 275) 
among the total cohort. In contrast, the popula-
tion prevalence of acromegaly is estimated at 
only 6 per 100,000 population, with an incidence 
of 3 to 4 per million per year.2 Given the fre-
quency of the c.924G→C substitution, I would 
urge caution in interpreting it as a disease-associ-
ated variant.
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The Authors Reply: Microduplications on chro-
mosome Xq26.3 cause X-linked acrogigantism 
(X-LAG). The expression of GPR101 (alone among 
the duplicated genes on Xq26.3) was highly up-
regulated in pituitary tumors obtained from pa-
tients with X-LAG. We therefore assessed wheth-
er genetic variants in GPR101 were present among 
a large, international sample of patients with 
acromegaly. Sequence analysis showed a mis-
sense change, c.924G→C (p.E308D; single-nucle-
otide polymorphism [SNP], rs73637412) in 4.4% 
of patients with acromegaly, predominantly in 
tumor DNA, including a sample obtained from a 
patient in whom the mutation was not present in 
peripheral DNA. This finding contrasted with a 
low prevalence of p.E308D in online databases. In 
keeping with this result, Kamenický et al. indi-
cate that p.E308D also occurs in a minority of 
unselected patients with acromegaly.
We found that p.E308D had functional effects: 
it significantly increased the release of growth 
hormone in somatomammotroph cells. We agree 
with Roohi that the frequencies of mutations 
vary according to the database that is used. In 
the current 1000 Genomes Project release, for ex-
ample, c.924G accounts for only 3 of 3775 alleles 
(0.0008) and is not present in other databases. 
Also, estimates of the prevalence of rare condi-
tions such as acromegaly (currently, 1:8000)1 
should be used cautiously when calculating over-
all allelic frequencies. SNP rs73637412 describes 
both p.E308D (encoded by c.924G→C) and its 
synonymous counterpart, c.924G→A. The syn-
onymous variant is reported at a lower frequency 
in the ExAC Browser than in other databases, 
suggesting that variant-calling may explain dis-
crepancies among online data. Accurate se-
quence determination is needed to distinguish 
between p.E308D and its synonymous variant in 
every sample.
Even if p.E308D is present in unaffected per-
sons, there are other genetic defects leading to 
acromegaly that are also present in the general 
population: the penetrance of AIP mutations is 
low (20 to 40%),2 and unaffected carriers 
abound.3,4 The fact that p.E308D may also be 
present de novo in pituitary tumors, as well as 
constitutively, is supportive of this variant and 
possibly the new one identified by Kamenický 
et al. (p.D366E), since they are factors that can 
alter somatotrope function and that may con-
tribute to the development of acromegaly.
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